Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (BCTX)
NASDAQ:BCTX
BCTX Stock Chart & Stats
$8.95
-$0.02(-3.38%)
At close: 4:00 PM EST
$8.95
-$0.02(-3.38%)
Day’s Range― - ―
52-Week Range$6.00 - $102.00
Previous Close$0.41
Volume996.24K
Average Volume (3M)71.25K
Market Cap
C$17.08M
Enterprise Value$0.00
Total Cash (Recent Filing)C$10.18M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.38
Shares Outstanding1,883,906
10 Day Avg. Volume65,395
30 Day Avg. Volume71,255
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$40.04Price Target Upside347.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBria-IMT improves progression-free survival in delayed-type hypersensitivity positive patients, showing statistically significant benefits across all treatment arms.
Enrollment And Trial ExpansionThe Phase 3 trial now has 70 sites open for enrollment, largely picking up the speed for enrollment.
Safety ProfileBria-IMT's safety and tolerability profile remains favorable, with no interstitial lung disease or CNS complications observed.
Bears Say
BriaCell Therapeutics News
BCTX FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was $6.00 and its highest was $102.00 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$17.08M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Mar 18, 2026 which is in 87 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Dec 11, 2025. The company reported -$4.384 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.384.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Undervalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 1,883,906 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -$4.384 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.468%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in BCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
BCTX Stock 12 Month Forecast
Average Price Target
$40.04
▲(347.32% Upside)
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Ownership Overview
23.70% Insiders
<0.01% Other Institutional Investors
76.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---